Associations between second-generation antipsychotics and metabolic outcomes in patients with schizophrenia and metabolic abnormalities
{{output}}
Second-generation antipsychotics (SGAs) were found to have varying metabolic side-effects for patients with schizophrenia, while no studies have examined the associations between adding or switching low-risk SGAs and metabolic outcomes. This real-world observa... ...
